Cardiopulmonary toxicity of thoracic radiotherapy CLARIFY
Research type
Research Study
Full title
Cardiopulmonary toxicity of thoracic radiotherapy CLARIFY
IRAS ID
250016
Contact name
Nazia Mohammed
Contact email
Sponsor organisation
University Medical Centre Groningen
Duration of Study in the UK
3 years, 11 months, 29 days
Research summary
Lung cancer is the most common cancer diagnosed in men and women and is the leading cause of cancer mortality. A large proportion of patients are diagnosed with locally advanced lung cancer and treatment with chemoradiation is potentially curative. Oesophageal cancer is another thoracic cancer which is usually diagnosed at a later stage and treatment given is chemo-radiation. However outcomes remain poor in comparison with the other common cancer types. There is increasing evidence that chemo-radiation which can affect normal organs in the chest - namely the lungs ha an additional detrimental effect on the heart, but the evidence is lacking. This study will use echocardiograms and blood tests to investigate changes to the heart and lungs as a result of chemo-radiation. In particular research in animal models have shown a form of cardiopulmonary injury, namely pulmonary hypertension which can limit life expectancy itself but can be treated with medication if recognised. This study will be focussing on looking for signs and symptoms related to pulmonary hypertension.
REC name
West of Scotland REC 4
REC reference
19/WS/0039
Date of REC Opinion
1 Jul 2019
REC opinion
Further Information Favourable Opinion